X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs J.B.CHEMICALS - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. J.B.CHEMICALS WOCKHARDT LTD./
J.B.CHEMICALS
 
P/E (TTM) x -19.1 17.7 - View Chart
P/BV x 2.0 2.4 84.4% View Chart
Dividend Yield % 0.0 0.2 1.2%  

Financials

 WOCKHARDT LTD.   J.B.CHEMICALS
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
J.B.CHEMICALS
Mar-16
WOCKHARDT LTD./
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,012318 318.1%   
Low Rs532200 266.4%   
Sales per share (Unadj.) Rs355.9148.0 240.5%  
Earnings per share (Unadj.) Rs-60.319.1 -315.9%  
Cash flow per share (Unadj.) Rs-46.823.9 -195.3%  
Dividends per share (Unadj.) Rs0.010.50 2.0%  
Dividend yield (eoy) %00.2 0.7%  
Book value per share (Unadj.) Rs257.8128.9 199.9%  
Shares outstanding (eoy) m110.6384.82 130.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.7 124.0%   
Avg P/E ratio x-12.813.6 -94.4%  
P/CF ratio (eoy) x-16.510.8 -152.7%  
Price / Book Value ratio x3.02.0 149.2%  
Dividend payout %02.6 -0.6%   
Avg Mkt Cap Rs m85,37921,951 388.9%   
No. of employees `0006.32.7 228.7%   
Total wages/salary Rs m9,3711,841 508.9%   
Avg. sales/employee Rs Th6,295.04,590.9 137.1%   
Avg. wages/employee Rs Th1,498.3673.4 222.5%   
Avg. net profit/employee Rs Th-1,066.3592.1 -180.1%   
INCOME DATA
Net Sales Rs m39,36912,551 313.7%  
Other income Rs m1,202542 222.0%   
Total revenues Rs m40,57113,093 309.9%   
Gross profit Rs m182,055 0.9%  
Depreciation Rs m1,495412 362.6%   
Interest Rs m2,55596 2,669.7%   
Profit before tax Rs m-2,8302,088 -135.5%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m257469 54.8%   
Profit after tax Rs m-6,6691,619 -412.0%  
Gross profit margin %016.4 0.3%  
Effective tax rate %-9.122.5 -40.4%   
Net profit margin %-16.912.9 -131.3%  
BALANCE SHEET DATA
Current assets Rs m33,7967,778 434.5%   
Current liabilities Rs m26,9174,358 617.6%   
Net working cap to sales %17.527.2 64.1%  
Current ratio x1.31.8 70.4%  
Inventory Days Days7955 145.1%  
Debtors Days Days8980 111.5%  
Net fixed assets Rs m39,6645,713 694.3%   
Share capital Rs m553170 326.2%   
"Free" reserves Rs m27,96810,547 265.2%   
Net worth Rs m28,52210,937 260.8%   
Long term debt Rs m21,7310-   
Total assets Rs m81,62015,574 524.1%  
Interest coverage x-0.122.8 -0.5%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.50.8 59.8%   
Return on assets %-5.011.0 -45.8%  
Return on equity %-23.414.8 -158.0%  
Return on capital %-7.720.0 -38.4%  
Exports to sales %048.7 0.0%   
Imports to sales %07.1 0.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs mNA889 0.0%   
Fx inflow Rs m9,8076,169 159.0%   
Fx outflow Rs m1,7891,285 139.2%   
Net fx Rs m8,0194,884 164.2%   
CASH FLOW
From Operations Rs m6841,397 49.0%  
From Investments Rs m6,302-320 -1,967.7%  
From Financial Activity Rs m-7,695-1,196 643.5%  
Net Cashflow Rs m-664-102 649.1%  

Share Holding

Indian Promoters % 74.5 55.4 134.5%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 2.3 3.4 67.8%  
FIIs % 7.7 3.9 197.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 37.0 41.6%  
Shareholders   67,757 30,437 222.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare WOCKHARDT LTD. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Nov 16, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS